Navigation Links
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
Date:6/29/2009

--Dr. Sherman also elected President of the Drug Information Association (DIA)--

NORTHBROOK, Ill., June 29 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P., as its executive vice president and chief medical officer.

Dr. Sherman brings more than 20 years of pharmaceutical experience to Horizon and will lead the regulatory and clinical strategy for Horizon's investigational therapies for mild-to-moderate arthritis and pain, including HZT-501, a fixed-dose combination tablet containing the most prescribed non-steroidal anti-inflammatory drug (NSAID), ibuprofen, with a high dose of the most potent H2 antagonist, famotidine. HZT-501 was shown to significantly reduce the incidence of NSAID-induced upper gastrointestinal ulcers in patients with mild-to-moderate pain in two Phase 3 studies.

Dr. Sherman joins Horizon from IDM Pharma, which was recently purchased by Takeda Pharmaceuticals Limited, where he led the clinical, regulatory, and development teams that secured European Commission approval for MEPACT(R) (mifamurtide, L-MTP-PE), a treatment for non-metastatic, resectable osteosarcoma. Prior to IDM Pharma, Dr. Sherman served as vice president of clinical science at Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he was focused on developing Takeda's oncology pipeline. Dr. Sherman also held the position of chief medical officer and executive vice president at NeoPharm, Inc., and held numerous research development and marketing roles at Searle/Pharmacia, including responsibility for the COX-2 (Celebrex) oncology program.

"Dr. Sherman has significant experience in the biotechnology and pharmaceutical industry, with a proven track record of success in bringing drugs through the regulatory process," said Timothy P. Walbert, president and chief executive officer of Horizon Therapeutics. "Dr. Sherman will oversee the preparation and submission of the HZT-501 regulatory applications to U.S. and European regulatory authorities, while helping us manage the clinical development of our other pain therapies."

In addition to his Horizon appointment, Dr. Sherman was recently elected President of the Drug Information Association (DIA), a global, nonprofit, multidisciplinary, professional association of approximately 18,000 members which provides a neutral forum for sharing information that optimizes the process of drug development and lifecycle management. He has been a member of the DIA Board of Directors for nearly seven years and in 2001, received the association's "Outstanding Service Award."

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use
2. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
3. Horizon Therapeutics Announces Senior Management Appointments
4. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
5. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
6. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
7. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
8. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
9. BioHorizons Announces the Purchase of Implant Logic Systems
10. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
11. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):